Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 14, 2023 16:05 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results

Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results
November 07, 2023 16:05 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023

Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023
August 03, 2023 16:05 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter 2023 Financial Results on August 10, 2023

NEWTOWN, Pa., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and...
June 14, 2023 08:00 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics Presents Preclinical Data on Narazaciclib at the 17th International Conference on Malignant Lymphoma

NEWTOWN, Pa., June 14, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and...
May 15, 2023 16:18 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

NEWTOWN, Pa., May 15, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
May 11, 2023 08:00 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics Doses First Patient in Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer

Prior data provide clinical proof-of-concept for narazaciclib’s mechanism of action in endometrial cancer Preliminary data from trial’s Phase 1 portion expected in 4Q 2023 NEWTOWN, Pa., May 11,...